UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Long‐term safety and efficacy results in hepatitis C virus genotype 1‒infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ‐I and TOPAZ‐II trials

Journal of viral hepatitis, 2020-05, Vol.27 (5), p.497-504

2020

Volltextzugriff (PDF)

Electrocatalytic Proton Reduction by Phosphido-Bridged Diiron Carbonyl Compounds: Distant Relations to the H-Cluster?

Inorganic chemistry, 2004-09, Vol.43 (18), p.5635-5644

2004

Volltextzugriff (PDF)

Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C‐Registry

Liver international, 2021-07, Vol.41 (7), p.1518-1522

2021

Volltextzugriff (PDF)

Expert opinion on managing chronic HCV in patients with neuropsychiatric manifestations

Antiviral therapy, 2018, Vol.23 (Suppl 2), p.47-55

2018

Volltextzugriff (PDF)

Expert opinion on the management of renal manifestations of chronic HCV infection

Antiviral therapy, 2018, Vol.23 (Suppl 2), p.57-67

2018

Volltextzugriff (PDF)

The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real‐world data from the German Hepatitis C‐Registry (DHC‐R)

Journal of viral hepatitis, 2021-10, Vol.28 (10), p.1474-1483

2021

Volltextzugriff (PDF)

Expert opinion on managing chronic HCV in patients with mixed cryoglobulinaemia vasculitis

Antiviral therapy, 2018, Vol.23 (Suppl 2), p.1-9

2018

Volltextzugriff (PDF)

THU440 - Real-world clinical practice outcomes in hepatitis C-infected patients with psychiatric and substance use disorders treated with glecaprevir/pibrentasvir for 8 or 12 weeks: a pooled analysis across nine countries

Journal of hepatology, 2020-08, Vol.73, p.S358-S359

2020

Volltextzugriff (PDF)

Real-world clinical practice outcomes in hepatitis C-infected patients with psychiatric and substance use disorders treated with glecaprevir/pibrentasvir for 8 or 12 weeks: a pooled analysis across nine countries

Journal of hepatology, 2020-08, Vol.73, p.S358-S359

2020

Volltextzugriff (PDF)

THU-151-Real-world effectiveness and safety of glecaprevir plus pibrentasvir in HCV: A multi-country analysis of postmarketing observational studies

Journal of hepatology, 2019-04, Vol.70 (1), p.e228-e228

2019

Volltextzugriff (PDF)

Expert opinion on managing chronic HCV infection in patients with type 2 diabetes mellitus

Antiviral therapy, 2018, Vol.23 (Suppl 2), p.11-21

2018

Volltextzugriff (PDF)

Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

Advances in therapy, 2020-09, Vol.37 (9), p.4033-4042

2020

Volltextzugriff (PDF)

Expert opinion on managing chronic HCV in patients with non-Hodgkin lymphoma and other extrahepatic malignancies

Antiviral therapy, 2018, Vol.23 (Suppl 2), p.23-33

2018

Volltextzugriff (PDF)

Expert opinion on managing chronic HCV in patients with cardiovascular disease

Antiviral therapy, 2018, Vol.23 (Suppl 2), p.35-46

2018

Volltextzugriff (PDF)

Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis

Journal of viral hepatitis, 2019-08, Vol.26 (8), p.951-960

2019

Volltextzugriff (PDF)

Real‐world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1‐ and 4‐infected patients with diverse comorbidities and comedications: A pooled analysis of post‐marketing observational studies from 13 countries

Journal of viral hepatitis, 2019-06, Vol.26 (6), p.685-696

2019

Volltextzugriff (PDF)

Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real‐world cohorts

Journal of viral hepatitis, 2022-12, Vol.29 (12), p.1050-1061

2022

Volltextzugriff (PDF)

Mo1393 - Integrated Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Psychiatric Disorders

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-1192-S-1192

2018

Volltextzugriff (PDF)

SAT-255-Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials

Journal of hepatology, 2019-04, Vol.70 (1), p.e745-e746

2019

Volltextzugriff (PDF)

XAFS of short-lived reduction products of structural and functional models of the [Fe–Fe] hydrogenase H-cluster

Radiation physics and chemistry (Oxford, England : 1993), 2006-11, Vol.75 (11), p.1878-1883

2006

Volltextzugriff (PDF)

Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study

Advances in therapy, 2019-12, Vol.36 (12), p.3458-3470

2019

Volltextzugriff (PDF)

Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts

Advances in therapy, 2021-06, Vol.38 (6), p.3409-3426

2021

Volltextzugriff (PDF)

Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

Advances in therapy, 2020-11, Vol.37 (11), p.4755-4756

2020

Volltextzugriff (PDF)

Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir

Infectious diseases and therapy, 2021-12, Vol.10 (4), p.2203-2222

2021

Volltextzugriff (PDF)

Addressing HCV Elimination Barriers in Italy: Healthcare Resource Utilization and Cost Impact Using 8 Weeks’ Glecaprevir/Pibrentasvir Therapy

Infectious diseases and therapy, 2021-06, Vol.10 (2), p.763-774

2021

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(34)

Sprache

Englisch
(34)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Long‐term safety and efficacy results in hepatitis C virus genotype 1‒infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ‐I and TOPAZ‐II trials

Electrocatalytic Proton Reduction by Phosphido-Bridged Diiron Carbonyl Compounds: Distant Relations to the H-Cluster?

Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C‐Registry

Expert opinion on managing chronic HCV in patients with neuropsychiatric manifestations

Expert opinion on the management of renal manifestations of chronic HCV infection

The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real‐world data from the German Hepatitis C‐Registry (DHC‐R)

Expert opinion on managing chronic HCV in patients with mixed cryoglobulinaemia vasculitis

THU440 - Real-world clinical practice outcomes in hepatitis C-infected patients with psychiatric and substance use disorders treated with glecaprevir/pibrentasvir for 8 or 12 weeks: a pooled analysis across nine countries

Real-world clinical practice outcomes in hepatitis C-infected patients with psychiatric and substance use disorders treated with glecaprevir/pibrentasvir for 8 or 12 weeks: a pooled analysis across nine countries

THU-151-Real-world effectiveness and safety of glecaprevir plus pibrentasvir in HCV: A multi-country analysis of postmarketing observational studies

Expert opinion on managing chronic HCV infection in patients with type 2 diabetes mellitus

Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

Expert opinion on managing chronic HCV in patients with non-Hodgkin lymphoma and other extrahepatic malignancies

Expert opinion on managing chronic HCV in patients with cardiovascular disease

Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis

Real‐world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1‐ and 4‐infected patients with diverse comorbidities and comedications: A pooled analysis of post‐marketing observational studies from 13 countries

Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real‐world cohorts

Mo1393 - Integrated Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Psychiatric Disorders

SAT-255-Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials

XAFS of short-lived reduction products of structural and functional models of the [Fe–Fe] hydrogenase H-cluster

Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study

Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts

Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir

Addressing HCV Elimination Barriers in Italy: Healthcare Resource Utilization and Cost Impact Using 8 Weeks’ Glecaprevir/Pibrentasvir Therapy

Suchergebnisse filtern